<DOC>
	<DOCNO>NCT02509169</DOCNO>
	<brief_summary>An open-labeled , randomize , active-controlled phase II study investigate clinical efficacy immunoreaction use trans-catheter arterial embolization ( TAE ) combine p53 gene therapy treatment advance hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>Trans-catheter Arterial Embolization Combined With p53 Gene Therapy Treatment Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>Treatment option advance HCC limit due patient ' poor condition , advanced stage , concomitant intra- extra-liver disease , resistance chemo- radio-therapy . Trans-catheter embolization ( TAE ) safe locoregional treatment advance HCC p53 gene multiple anticancer function , method immune-inhibitory effect chemo- radio-therapy . The objective study investigate clinical efficacy immunoreaction usingTAE plus recombinant adenoviral human p53 gene ( rAd-p53 ) treatment advance HCC .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>histopathologically diagnose unresectable HCC 18 year old Eastern Cooperative Oncology Group ( ECOG ) score 02 Barcelona Clinic Liver Cancer ( BCLC ) Stage B C ChildPugh score A B ; normal test hemogram , blood coagulation , liver kidney function sign informed consent form . hypersensitive study drug With abnormal coagulation condition bleed disorder infection serious condition prevent use study treatment pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>